ALK5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린

본 개시내용은 액티빈 수용체-유사 키나제 5 (ALK5)의 억제제를 제공한다. 또한, ALK5의 활성을 조절하는 방법 및 ALK5에 의해 매개되는 장애를 치료하는 방법이 개시된다. The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5...

Full description

Saved in:
Bibliographic Details
Main Authors SULLIVAN STEVEN D. E, KULYK SVITLANA, ALLEGRETTI PAUL, KOZAK JENNIFER, LOO MANDY, HUGHES ADAM D, OWENS CHRISTINA, FENSTER ERIK, ZHAO CHEN
Format Patent
LanguageKorean
Published 26.07.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:본 개시내용은 액티빈 수용체-유사 키나제 5 (ALK5)의 억제제를 제공한다. 또한, ALK5의 활성을 조절하는 방법 및 ALK5에 의해 매개되는 장애를 치료하는 방법이 개시된다. The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
Bibliography:Application Number: KR20227020772